Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies

Amyotrophic Lateral Sclerosis Clinical Trial

— SLA-DOM  

Official title:

Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03367650
• Other study ID #: RBM-PAP-2013/55
• Status: Recruiting
• Phase: N/A
• First received: November 28, 2017
• Last updated: December 4, 2017
• Start date: May 13, 2014
• Est. completion date: May 13, 2023

Study information

• Verified date: November 2017
• Source: Centre Hospitalier Universitaire de Pointe-a-Pitre
• Contact: Chantal LERUS, Director of Clinical Research
• Phone: 0590 93 46 86
• Email: chantal.lerus[@]chu-guadeloupe.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The diagnosis and the follow-up of the patients reached of SLA is centralized, since a few years, at the the Caribbean Reference center of the rare neurological diseases (CERCA labélisé in 2006) in Martinique and at the Unity of coverage of the neuromuscular Diseases, SLA and the rare neurological diseases (create in 2010) in Guadeloupe. Several phenotypic characteristics seemed to us to take out again data collected during the follow-up of the patients (26 in Guadeloupe, since the creation of the unity) in particular patients' high proportion of exceptionally long evolution (more than 10 years). Besides, we diagnosed several cases (10 cases in Guadeloupe since 2000) of association SLA- Parkinsonien Syndrome.

This association, considered as exceptional could establish a particular phenotypic entity which we would like to describe. We are interested also originally geographical of the patients, with the hypothesis that he could exist in the Antilles one or several geographical isolates of the disease allowing to lead a étiologique investigation in search of a possible genetic or environmental cause.

Description:

The amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscular paralysis due to degeneration of motor neurons in the primary motor cortex, corticospinal pathway, brain stem and spinal cord. The incidence is estimated at 2/100 000 per year and prevalence at approximately 4/100000.

Various clinical forms are described. The disease is fatal is 3-5 years on average.

The majority of cases are sporadic and of unknown origin but 5-10% are familial and present for 20% of them, mutations in the SOD1 (21q22.11) gene. Other genes have recently been implicated in ALS. Environmental toxic factors have been extensively researched. Beta-methylamino-L-alanine (BMAA), a neurotoxic nonprotein amino acid produced by most cyanobacteria, has been proposed to be the causative agent of the ALS-Parkinsonism Complex on the island of Guam in the Pacific Ocean.

Epidemiology and clinical features of ALS have never been studied in Caribbean countries.

The main purpose of the study will be to evaluate the incidence of ALS in Guadeloupe and Martinique.

Secondary purposes will be:

1. to evaluate the presence of specific phenotypic features;

2. to establish he prognosis of different clinical forms;

3. to study the genes implicated in ALS and quantify theexposure to BMAA.

Since 2000, the diagnosis of ALS is made in about 20 patients per year in Guadeloupe and Martinique(for a total population of 800000 inhabitants) but the incidence and the clinical presentation of ALS in the French West Indiesare unknown.

The exceptional association of ALS and parkinsonism is regularly observed in Guadeloupe. We propose to perform a prospective descriptive and longitudinal epidemiological study to determine the incidence of ALSin the French West Indies. In parallel we will study the involvement of genetic andenvironmental toxic factors as etiological factor for this disease.

Primary outcome:

• the impact of ALS in Guadeloupe and Martinique

Secondary outcomes:

• Assess the clinical characteristics (presence of phenotypic features?),

• the prognosis of different clinical forms study,

• to establish the genetic factors of the ALS and to search potential environmental factors

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: May 13, 2023
• Est. primary completion date: May 13, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient or third-party responsible for receiving information on the study and who signed informed consent ;

• Patient age over 18 years;

• Patient living in the Antilles;

• Patient with ALS or SLP (primary lateral sclerosis, pure central form of ALS).

Exclusion Criteria:

• Patient non-affiliated to the social security scheme ;

• in case of difficulty of monitoring patient, exclusion of the longitudinal study.

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Dietary Supplement:
• Blood sample and environmental survey
The intervention corresponds to a 10 ml of Blood sample and an environmental survey.

Locations

Country	Name	City	State
Guadeloupe	Hospital University Center of Pointe-à-Pitre	Pointe-à-Pitre
Martinique	Hospital University Center of Martinique	Fort-de-France

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Pointe-a-Pitre

Countries where clinical trial is conducted

Guadeloupe,  Martinique, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the impact of amyotrophic lateral sclerosis in Guadeloupe and Martinique	Number of new cases per year.	Through study completion, an average of 6 years
Secondary	Estimate prevalence of the ALS	Determine the total number of case of ALS diagnosed in Guadeloupe and Martinique on the duration of the study	Through study completion, an average of 6 years
Secondary	Clinical criteria of SLA	General, neurological, digestive clinical examination and cardiorespiratory complete and the realization of the score " ALS funtional rating scale "	Through study completion, an average of 9 years
Secondary	Study the genetic factors of the ALS	Search for transfers of genes TARDBP, VCP, SOD1: According to the genealogical data, we shall target the possible family forms to test at these patient's the various genes known and involved in the disease (transfers of the gene SOD1 (21q22.11), of the gene TARDBP (1p36.22) coding the protein TAR DNA-binding protein 43 (TDP-43) and of the gene VCP (9p13.3) coding for the protein Valosin Containing Protein).; For the sporadic cases the analysis of these genes will be realized on the whole studied population.; For the family cases the genetic study will be spread in the whole family.	Through study completion, an average of 9 years